Author Contributions
Conceptualization, Y.-C.L. and H.L.; Data curation, H.-T.Y., R.-X.L., Q.-Z.Y., H.-C.L., R.-F.G. and L.-H.W.; Formal analysis, H.-T.Y., R.-X.L. and L.-H.W.; Investigation, Y.-C.L. and H.-T.Y.; Methodology, Y.-C.L., H.-T.Y. and L.-M.L.; Writing-original draft, H.-T.Y. and Q.-Z.Y.; Writing—review & editing, Y.-C.L. and R.-X.L.; Supervision, Y.-C.L., L.-M.L. and H.L.; Fund acquisition, Y.-C.L. and H.L. All authors have read and agreed to the published version of the manuscript.
Figure 1.
The ORTEP drawing for the crystal structure of EFX-Ca.
Figure 1.
The ORTEP drawing for the crystal structure of EFX-Ca.
Figure 2.
The water solubility of EFX-Ca at room temperature was determined by the Lambert–Beer law based on the standard line of the water solubility of EFX-Ca derived from a series of determined concentrations. The concentration of the working solution of EFX-Ca indicated by the UV-Vis spectrum was based on a 30× dilution on the saturated aqueous solution of EFX-Ca.
Figure 2.
The water solubility of EFX-Ca at room temperature was determined by the Lambert–Beer law based on the standard line of the water solubility of EFX-Ca derived from a series of determined concentrations. The concentration of the working solution of EFX-Ca indicated by the UV-Vis spectrum was based on a 30× dilution on the saturated aqueous solution of EFX-Ca.
Figure 3.
The time-dependent effects on the body weight of the tested KM mice after the oral administration of EFX-Ca at different dosages (2000, 3031, 4595, 6964, 10,556 and 16,000 mg/kg).
Figure 3.
The time-dependent effects on the body weight of the tested KM mice after the oral administration of EFX-Ca at different dosages (2000, 3031, 4595, 6964, 10,556 and 16,000 mg/kg).
Figure 4.
Histopathological images under 40× magnification on the main organs from the dead mice after the oral administration of EFX, EFX-Na, and EFX-Ca, in which the histologic tissue slices of (a) heart, (b) liver, (c) spleen, (d) lung, (e) kidney, (f) large intestine, and (g) small intestine were stained and visualized. Number 0, 1, 2, 3 indicates the effect of EFX, EFX-Ca and EFX-Na for each organ, respectively.
Figure 4.
Histopathological images under 40× magnification on the main organs from the dead mice after the oral administration of EFX, EFX-Na, and EFX-Ca, in which the histologic tissue slices of (a) heart, (b) liver, (c) spleen, (d) lung, (e) kidney, (f) large intestine, and (g) small intestine were stained and visualized. Number 0, 1, 2, 3 indicates the effect of EFX, EFX-Ca and EFX-Na for each organ, respectively.
Figure 5.
The relationship between drug concentration and the elimination time in plasma samples from the tested SD rats treated with EFX-Ca and EFX at different time points (0, 0.083, 0.333, 0.5, 0.75, 1, 3, 4, 6, 8, 10, 12, and 24 h).
Figure 5.
The relationship between drug concentration and the elimination time in plasma samples from the tested SD rats treated with EFX-Ca and EFX at different time points (0, 0.083, 0.333, 0.5, 0.75, 1, 3, 4, 6, 8, 10, 12, and 24 h).
Figure 6.
The inhibition effect of EFX-Ca, compared with EFX at the same concentrations (0.01, 0.1, 1 μM), on the observed neutrophil cluster aggregation under the CuSO4-induced mode of the transgenic zebrafish line Tg(mpx:eGFP). The partial magnified images of the latter part of the zebrafish were shown on the right side. The red arrows in the right side represent aggregations of neutrophils.
Figure 6.
The inhibition effect of EFX-Ca, compared with EFX at the same concentrations (0.01, 0.1, 1 μM), on the observed neutrophil cluster aggregation under the CuSO4-induced mode of the transgenic zebrafish line Tg(mpx:eGFP). The partial magnified images of the latter part of the zebrafish were shown on the right side. The red arrows in the right side represent aggregations of neutrophils.
Figure 7.
(A) The anti-inflammatory effect of EFX-Ca, compared with EFX at the same concentrations (0.01, 0.1, 1 μM), on the H2O2-induced ROS production in zebrafish model, indicated by the green fluorescence probe and visualized by the added DCFH-DA. (B) The quantitative results for the oxidative stress in zebrafish, represented by the histogram on the right side, were statistically analyzed based on examining the integrated optical density (IOD) of the green fluorescence in the tested zebrafish. Mean ± SD: * p < 0.05, *** p < 0.001.
Figure 7.
(A) The anti-inflammatory effect of EFX-Ca, compared with EFX at the same concentrations (0.01, 0.1, 1 μM), on the H2O2-induced ROS production in zebrafish model, indicated by the green fluorescence probe and visualized by the added DCFH-DA. (B) The quantitative results for the oxidative stress in zebrafish, represented by the histogram on the right side, were statistically analyzed based on examining the integrated optical density (IOD) of the green fluorescence in the tested zebrafish. Mean ± SD: * p < 0.05, *** p < 0.001.
Table 1.
Crystallographic and refinement parameters for EFX-Ca.
Table 1.
Crystallographic and refinement parameters for EFX-Ca.
Empirical Formula | C38H53CaF2N6O11 |
---|
Formula weight | 847.94 |
Temperature / K | 296.15 |
Crystal system | Monoclinic |
Space group | C2/c |
a/Å, b/Å, c/Å | 14.891(3), 26.250(5), 10.710(2) |
α/°, β/°, γ/° | 90.00, 102.825(3), 90.00 |
Volume/Å3 | 4081.9(14) |
Z | 4 |
ρcalc/mg mm−3 | 1.380 |
μ/mm−1 | 0.229 |
F (000) | 1796 |
Crystal size/mm3 | 0.40 × 0.20 × 0.12 |
2θ range for data collection | 3.1 to 52.74° |
Index ranges | −18 ≤ h ≤ 18, −32 ≤ k ≤ 32, −13 ≤ l ≤ 13 |
Reflections collected | 24,569 |
Independent reflections | 4187 [R(int) = 0.0336] |
Data/restraints/parameters | 4187/9/279 |
Goodness-of-fit on F2 | 1.056 |
Final R indexes [I > 2σ (I)] | R1 = 0.0384, wR2 = 0.1116 |
Final R indexes [all data] | R1 = 0.0487, wR2 = 0.1200 |
Largest diff. peak/hole/e Å−3 | 0.360/−0.512 |
Table 2.
The antibacterial activity against five bacteria of EFX and EFX-Ca shown as MIC and MBC values (μg/mL).
Table 2.
The antibacterial activity against five bacteria of EFX and EFX-Ca shown as MIC and MBC values (μg/mL).
Type of Bacteria | EFX | EFX-Ca |
---|
MIC | MBC | MIC | MBC |
---|
S. aureus | 0.25 | 0.25 | 0.25 | 0.25 |
E. coli | 0.0625 | 0.0625 | 0.03125 | 0.0625 |
S. typhi | 0.03125 | 0.0625 | 0.03125 | 0.0625 |
P. aeruginosa | 0.125 | 0.125 | 0.125 | 0.125 |
P. vulgaris | 0.125 | 0.125 | 0.125 | 0.125 |
Table 3.
Changes in the body weight (g, ± SD) of the tested KM mice caused by EFX-Ca at different dosages (2000, 3031, 4595, 6964, 10,556 and 16,000 mg/kg).
Table 3.
Changes in the body weight (g, ± SD) of the tested KM mice caused by EFX-Ca at different dosages (2000, 3031, 4595, 6964, 10,556 and 16,000 mg/kg).
Group | Dose (mg/kg) | ± SD)
|
---|
Day-0 | Day-1 | Day-4 | Day-7 | Day-14 |
---|
Control | -- | 17.21 ± 1.25 | 21.57 ± 1.37 | 27.03 ± 1.53 | 30.47 ± 2.61 | 35.00 ± 5.19 |
1 | 16,000 | 17.84 ± 1.23 | 17.43 ± 1.95 * | 23.55 ± 2.66 | 29.15 ± 2.66 | 37.25 ± 4.57 |
2 | 10,556 | 17.67 ± 0.72 | 17.00 ± 0.30 * | 21.53 ± 2.10 * | 26.47 ± 3.50 * | 34.00 ± 7.50 |
3 | 6964 | 17.68 ± 0.88 | 17.21 ± 1.22 * | 16.89 ± 5.13 * | 23.11 ± 4.21 * | 29.30 ± 5.26 * |
4 | 4595 | 17.31 ± 1.05 | 17.09 ± 1.56 * | 20.10 ± 5.55 * | 26.43 ± 5.34 * | 33.60 ± 7.07 |
5 | 3031 | 18.32 ± 0.94 | 19.61 ± 1.23 * | 25.70 ± 1.24 | 28.44 ± 2.14 | 33.91 ± 5.25 |
6 | 2000 | 17.51 ± 1.14 | 19.77 ± 1.22 * | 25.91 ± 1.83 | 29.78 ± 3.46 | 33.33 ± 5.64 |
Table 4.
The acute toxicity test on KM mice administrated different dosages (2000, 3031, 4595, 6964, 10,556 and 16,000 mg/kg) of EFX-Ca, compared with EFX.
Table 4.
The acute toxicity test on KM mice administrated different dosages (2000, 3031, 4595, 6964, 10,556 and 16,000 mg/kg) of EFX-Ca, compared with EFX.
EFX-Ca |
Dose (mg/kg) | 2000 | 3031 | 4595 | 6964 | 10,556 | 16,000 |
Death number | 0 | 3 | 4 | 3 | 7 | 10 |
EFX |
Dose (mg/kg) | 2000 | 3031 | 4595 | 6964 | 10,556 | 16,000 |
Death number | 2 | 5 | 5 | 4 | 9 | 10 |
Table 5.
Main pharmacokinetic parameters of the plasma sample from the tested SD rats under the oral administration of EFX and EFX-Ca, respectively.
Table 5.
Main pharmacokinetic parameters of the plasma sample from the tested SD rats under the oral administration of EFX and EFX-Ca, respectively.
Parameter | Unit | EFX (10 mg/kg) | EFX-Ca (12 mg/kg) |
---|
Cmax | ng/mL | 830 | 1920 |
Tmax | H | 1 | 0.75 |
t1/2β | H | 2.43 | 4.41 |
AUC0−t | ng·h/mL | 2702.50 | 5875.83 |
Ke | --- | 0.28 | 0.16 |
Vd | mL/kg | 1053.16 | 267.44 |
Cl | mL/kg·h | 37.00 | 20.42 |
Table 6.
The statistical survival (death) of the tested zebrafish under the medicated bath of different concentrations (0.01, 0.1, 1, 10, 20 μM) of EFX-Ca or EFX.
Table 6.
The statistical survival (death) of the tested zebrafish under the medicated bath of different concentrations (0.01, 0.1, 1, 10, 20 μM) of EFX-Ca or EFX.
| EFX-Ca |
Control | 0.01 | 0.1 | 1 | 10 | 20 |
24 hpf | 28(2) | 24(6) | 26(4) | 28(2) | 26(4) | 30(0) |
48 hpf | 28(2) | 24(6) | 26(4) | 28(2) | 26(4) | 30(0) |
72 hpf | 28(2) | 24(6) | 26(4) | 28(2) | 26(4) | 30(0) |
96 hpf | 28(2) | 22(8) | 26(4) | 28(2) | 26(4) | 30(0) |
120 hpf | 28(2) | 22(8) | 26(4) | 28(2) | 26(4) | 30(0) |
| EFX |
Control | 0.01 | 0.1 | 1 | 10 | 20 |
24 hpf | 28(2) | 24(6) | 26(4) | 28(2) | 28(2) | 26(4) |
48 hpf | 28(2) | 24(6) | 26(4) | 28(2) | 28(2) | 26(4) |
72 hpf | 28(2) | 24(6) | 26(4) | 28(2) | 28(2) | 26(4) |
96 hpf | 28(2) | 24(6) | 26(4) | 28(2) | 28(2) | 26(4) |
120 hpf | 28(2) | 24(6) | 26(4) | 28(2) | 28(2) | 26(4) |
Table 7.
The survival numbers, cure rates, and relative weight gain rates on two typical broilers after drug-mixed feeding of EFX and different dosages of EFX-Ca, respectively.
Table 7.
The survival numbers, cure rates, and relative weight gain rates on two typical broilers after drug-mixed feeding of EFX and different dosages of EFX-Ca, respectively.
Type of Broilers | Group | Number | Survival Number | Cure Rate (%) | Average Weight Gain | Relative Weight Gain Rate (%) |
---|
AA | Control | 50 | 50 | 100 | 730 | 100 |
EFX | 50 | 31 | 62 | 380 | 52 |
EFX-Ca (High) | 50 | 30 | 60 | 250 | 34 |
EFX-Ca (Medium) | 50 | 39 | 78 | 140 | 19 |
EFX-Ca (Low) | 50 | 27 | 54 | 190 | 26 |
817 | Control | 50 | 50 | 100 | 600 | 100 |
EFX | 50 | 32 | 64 | 100 | 17 |
EFX-Ca (High) | 50 | 29 | 58 | 70 | 12 |
EFX-Ca (Medium) | 50 | 40 | 80 | 80 | 13 |
EFX-Ca (Low) | 50 | 44 | 88 | 280 | 47 |
Table 8.
The influence on the body weight, feed consumption and feed conversion ratios on two typical broilers after drug-mixed feeding of EFX and different dosage of EFX-Ca, respectively.
Table 8.
The influence on the body weight, feed consumption and feed conversion ratios on two typical broilers after drug-mixed feeding of EFX and different dosage of EFX-Ca, respectively.
Type of Broilers | Group | Average Initial Weight (g) | Average Final Weight (g) | Average Increment of Weight (g) | Total Feed Consumption (g) | Average Feed Consumption (g) | Feed Conversion Ratio (FCR) |
---|
AA | Control | 1500 ± 68 | 2230 ± 104 | 730 | 67,000 | 1340 | 1.84:1 |
EFX | 1630 ± 120 | 1880 ± 113 | 250 | 13,200 | 264 | 1.06:1 |
EFX-Ca (High) | 1520 ± 78 | 1750 ± 125 | 230 | 15,000 | 300 | 1.30:1 |
EFX-Ca (Medium) | 1360 ± 57 | 1640 ± 73 | 280 | 16,000 | 320 | 1.14:1 |
EFX-Ca (Low) | 1500 ± 94 | 1690 ± 95 | 190 | 11,000 | 220 | 1.16:1 |
817 | Control | 930 ± 71 | 1530 ± 74 | 600 | 51,000 | 1020 | 1.7:1 |
EFX | 890 ± 56 | 1030 ± 74 | 140 | 7300 | 146 | 1.04:1 |
EFX-Ca (High) | 920 ± 58 | 1000 ± 51 | 80 | 4500 | 90 | 1.13:1 |
EFX-Ca (Medium) | 870 ± 47 | 1010 ± 61 | 140 | 7500 | 150 | 1.07:1 |
EFX-Ca (Low) | 950 ± 56 | 1210 ± 67 | 260 | 14,000 | 280 | 1.08:1 |
Table 9.
Conditions for the drug-mixed feeding on two types of tested broilers.
Table 9.
Conditions for the drug-mixed feeding on two types of tested broilers.
Type of Broilers | Conditions | Compound in Each Group | Number | Dosage (Drug in Solution + Feed)/4 h |
---|
AA | Uninfected | Control | 50 | 1.5 kg |
infected | EFX | 50 | 11 g + 1.5 kg |
infected | EFX-Ca (High) | 50 | 14 g + 1.5 kg |
infected | EFX-Ca (Medium) | 50 | 9 g + 1.5 kg |
infected | EFX-Ca (Low) | 50 | 6 g + 1.5 kg |
817 | Uninfected | Control | 50 | 0.75 kg |
infected | EFX | 50 | 11 g + 0.75 kg |
infected | EFX-Ca (High) | 50 | 14 g + 0.75 kg |
infected | EFX-Ca (Medium) | 50 | 9 g + 0.75 kg |
infected | EFX-Ca (Low) | 50 | 6 g + 0.75 kg |